<DOC>
	<DOCNO>NCT02142322</DOCNO>
	<brief_summary>This Phase II Trial Perioperative Chemotherapy Oxaliplatin , 5-Fluorouracil , Leucovorin ( MODIFIED FOLFOX6 ) Patients Locally Advanced Operable Gastric Cancer .</brief_summary>
	<brief_title>Perioperative mFOLFOX-6 Locally Advanced Gastric Cancer</brief_title>
	<detailed_description>The main purpose study evaluate response rate ( clinical response pathological response ) oxaliplatin , 5-fluorouracil , leucovorin ( MODIFIED FOLFOX6 )</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Previously untreated patient pathologically proven advanced gastric adenocarcinoma regional LN metastasis eligible study ( clinical stage : cT24 N+ ) . At least one measurable regional lymph node metastasis accord Response Evaluation Criteria Solid Tumors ( RECIST v. 1.0 ) [ 17 ] require . Other eligibility criterion include age 18 75 year , Eastern Cooperative Oncology Group performance status ( ECOG PS ) 0 1 , prior chemotherapy radiotherapy , adequate bone marrow , hepatic renal function ( absolute neutrophil count [ ANC ] ≥ 1.5ⅹ109/L , platelet count ≥ 100ⅹ109/L , total bilirubin ≤ 1.5ⅹupper limit normal [ ULN ] , serum transaminase ≤ 2.5ⅹULN , alkaline phosphatase ≤ 2.5ⅹULN , serum creatinine ≤ 1.5ⅹULN actual calculate creatinine clearance ≥ 50 mL/min ) . Exclusion criterion include clinical stage T1 tumor , clinical radiologic evidence distant metastasis , intestinal obstruction impend obstruction , active tumor bleeding , interstitial pneumonitis symptomatic pulmonary fibrosis , peripheral neuropathy National Cancer Institute Common Toxicity Criteria ( NCICTC ) grade ≥1 , pregnant breastfeeding patient , serious disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>